Effect of oral nintedanib vs placebo on epistaxis in hereditary hemorrhagic telangiectasia: the EPICURE multicenter randomized double-blind trial
Angiogenesis · 2025-02 · 28 (1)
DOI: 10.1007/s10456-024-09962-4 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Angiogenesis, online erschienen am 24.12.2024. Verfasst von Ruben Hermann und 22 weiteren Autor:innen. Beteiligte Einrichtung: Service d'ORL, chirurgie cervico-faciale et d'audiophonologie, Hôpital Edouard Herriot, Hospices Civils de Lyon, 5 Place d'Arsonval, 69003, Lyon, Fra…. Hauptthemen laut MEDLINE: Telangiectasia, Hereditary Hemorrhagic, Epistaxis, Indoles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Epistaxis greatly affects patients with hereditary hemorrhagic telangiectasia (HHT). Although few systemic treatment exist, nintedanib, is a good candidate thanks to its anti-angiogenic activity. Our main objective was to evaluate the efficacy of oral nintedanib on epistaxis duration in HHT patients with moderate to severe epistaxis. This multicenter phase 2 randomized, placebo-controlled, double-blind trial was conducted between June 2020 and February 2023. Inclusion criteria were being over 18 years old and having a confirmed HHT diagnosis with an epistaxis severity score greater than 4. Sixty patients were randomized to receive either nintedanib or placebo for 12 weeks with a 12 week follow-up. The primary endpoint was the proportion of patients achieving a reduction of at least 50% in mean monthly epistaxis duration comparing the 8 weeks before treatment to the last 8 weeks of treatment. Main secondary outcomes included monthly duration and frequency of epistaxis and hemoglobin levels. Of the 60 randomized patients, 56 completed the trial. Thirteen patients (43%) in the nintedanib group vs 8 (27%) in the placebo group met the primary endpoint ( p = 0.28). We observed a significant decrease in median epistaxis (57% vs 27%, p = 0.013) and a significant increase in median hemoglobin levels (+ 18 vs − 1 g/L, p = 0.02) in the nintedanib vs the placebo group. Although we did not achieve our primary outcome, we observed a significant reduction in epistaxis duration and a significant increase in hemoglobin levels in patients treated with nintedanib. This supports the efficacy of nintedanib, and further studies are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service d'ORL, chirurgie cervico-faciale et d'audiophonologie, Hôpital Edouard Herriot, Hospices Civils de Lyon, 5 Place d'Arsonval, 69003, Lyon, France. ruben.hermann@chu-lyon.fr.
- Service de Médecine Interne, CHU Estaing, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
- Medical Genetics Department, University Hospital of Poitiers, 86000, Poitiers, France.
- Department of Internal Medicine and Clinical Immunology, Angers University Hospital, Angers, France.
- Assistance Publique-Hôpitaux de Paris, Service de Pneumologie et Centre de Compétence de la Maladie de Rendu Osler, Hôpital Tenon, 75020, Paris, France.
- Service de Médecine Interne A, Centre Hospitalier Universitaire, Montpellier, France.
Zitieren
APA
Hermann, R., Grobost, V., Le-Guillou, X., Lavigne, C., Parrot, A., Rivière, S., Séguier, J., Fargeton, A. E., de-Montigny, A., Huot, M., Decullier, E., Roux, A., Gervaise, C., Cartier, C., Dufour, X., Grall, M., Jegoux, F., Laccourreye, L., Michel, J., …, & Dupuis-Girod, S. (2025). Effect of oral nintedanib vs placebo on epistaxis in hereditary hemorrhagic telangiectasia: the EPICURE multicenter randomized double-blind trial. Angiogenesis, 28(1). https://doi.org/10.1007/s10456-024-09962-4
Vancouver
Hermann R, Grobost V, Le-Guillou X, Lavigne C, Parrot A, Rivière S, et al. Effect of oral nintedanib vs placebo on epistaxis in hereditary hemorrhagic telangiectasia: the EPICURE multicenter randomized double-blind trial. Angiogenesis. 2025;28(1). doi:10.1007/s10456-024-09962-4
BibTeX
@article{Hermann2025,
author = {Hermann, Ruben and Grobost, Vincent and Le-Guillou, Xavier and Lavigne, Christian and Parrot, Antoine and Rivière, Sophie and Séguier, Julie and Fargeton, Anne-Emmanuelle and de-Montigny, Aurélie and Huot, Margaux and Decullier, Evelyne and Roux, Adeline and Gervaise, Caroline and Cartier, César and Dufour, Xavier and Grall, Margaux and Jegoux, Frank and Laccourreye, Laurent and Michel, Justin and Saroul, Nicolas and Wagner, Isabelle and Kerjouan, Mallorie and Dupuis-Girod, Sophie},
title = {Effect of oral nintedanib vs placebo on epistaxis in hereditary hemorrhagic telangiectasia: the EPICURE multicenter randomized double-blind trial},
journal = {Angiogenesis},
year = {2025},
volume = {28},
number = {1},
doi = {10.1007/s10456-024-09962-4}
}
EUVIMED